Janux Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Janux Therapeutics, Inc. (JANX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $13.76 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $13.68, a 74.06% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $52.74, a 373.85% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.13, a 20.84% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $14.06, a 28.05% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $46.31, a 207.30% increase from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $15.07, a 9.20% increase from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $13.80, a 19.95% decline from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $17.24, a 61.27% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.76 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $13.68 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $46.31 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $46.81 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $47.69 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $52.74 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $15.07 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $14.56 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $12.49 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $11.13 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $13.80 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $13.90 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $13.91 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $14.06 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $17.24 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $17.48 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $17.67 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $19.54 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $10.69 10-K · filed 2022-03-18 | |||
| 2021-09-30 | $10.43 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $8.45 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |